Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InsmedINSM +36.22%70 Debt-to-EBITDA is -1.05 as of Mar. 2026. GuruFocus rates INSM with a GF Score™ of 70/100 and a GF Value™ of $187.82 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 298 Biotechnology companies, Insmed ranks worse than 335570.13% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Insmed's Debt-to-EBITDA or its related term are showing as below:
INSM'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.63 Med: -1.5 Max: -0.3
Current: -0.54
During the past 13 years, the highest Debt-to-EBITDA Ratio of Insmed was -0.30. The lowest was -2.63. And the median was -1.50.
INSM's Debt-to-EBITDA is ranked worse than 100% of 298
companies
in the Biotechnology industry
Industry Median: 1.23
vs INSM: -0.54
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Insmed Debt-to-EBITDA Related Terms
Insmed Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Insmed's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INSM vs INCY, BNTX, MRNA: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Insmed's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insmed Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Insmed's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Insmed's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Insmed (INSM) has a Debt-to-EBITDA of -1.05 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Insmed. According to the industry distribution chart, Insmed ranks #999999 out of 298 companies in the Biotechnology industry.
Is Insmed's Debt-to-EBITDA too high?
Insmed's current Debt-to-EBITDA is -1.05. Based on the distribution chart, Insmed ranks #999999 out of 298 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Insmed has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Insmed's Debt-to-EBITDA compare to INCY and BNTX?
According to the Biotechnology industry distribution chart, Insmed ranks #999999 out of 298 companies for Debt-to-EBITDA. This places Insmed in the lower half of its industry. The industry median Debt-to-EBITDA is 1.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.23, based on 298 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Insmed. For the Biotechnology industry, the median Debt-to-EBITDA is 1.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insmed's current Debt-to-EBITDA is -1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Based on GuruFocus' analysis, Insmed (INSM) is currently considered Possible Value Trap. The stock's GF Value™ is $187.82, compared to a current price of $134.89 — trading 28.2% below its estimated fair value. The current Debt-to-EBITDA is -1.05. Insmed's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Insmed (INSM), the current Debt-to-EBITDA is -1.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insmed (INSM) Overvalued in 2026?
Based on GuruFocus' analysis, Insmed stock appears to be undervalued.
The current stock price of $134.89 is trading 28.2% below its estimated GF Value™ of $187.82.
GuruFocus considers Insmed to be Possible Value Trap.
Key valuation signals for INSM:
Debt-to-EBITDA: -1.05
GF Value™: $187.82 vs. price of $134.89 (28.2% below fair value)
No single metric tells the full story. See the INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
70GF Score
Get the complete analysis for INSM
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INSM has been successfully added to your 
